{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:00:51Z","timestamp":1757779251206,"version":"3.37.3"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) is a rare but costly condition in the United States. Super-utilizers have been defined as a subset of the population with high health care encounters or expenditures. Although super-utilizers have been described in other disease states, little is known about super-utilizers among adults with SCD. This study aimed to characterize the differences in expenditures, overall health care encounters, and pain episode encounters between super-utilizers (top 10% expenditures) and lower-utilizers with SCD (high, top 10%-24.9%; moderate, 25%-49.9%; and low, bottom 50% expenditures). A retrospective longitudinal cohort of adults with SCD were identified using validated algorithms in MarketScan and Medicare claim databases from 2016 to 2020. Encounters and expenditures were analyzed from inpatient, outpatient, and emergency department settings. Differences in encounters and expenditures between lower-utilizers and super-utilizers were compared using logistic regression. Among super-utilizers, differences in encounters and expenditures were compared according to incidences of pain episode encounters. The study population included 5666 patients with commercial insurance and 8600 with Medicare. Adjusted total annual health care expenditure was 43.46 times higher for super-utilizers than for low-utilizers among commercial-insured and 13.37 times higher in Medicare-insured patients. Among super-utilizers, there were patients with few pain episode encounters who had higher outpatient expenditures than patients with a high number of pain episode encounters. Our findings demonstrate the contribution of expensive outpatient care among SCD super-utilizers, in which analyses of high expenditure have largely focused on short-term care. Future studies are needed to better understand super-utilizers in the SCD population to inform the effective use of preventive interventions and\/or curative therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010813","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:11:11Z","timestamp":1700676671000},"page":"224-233","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Comparing super-utilizers and lower-utilizers among commercial-\u00a0and Medicare-insured adults with sickle cell disease"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-6232","authenticated-orcid":false,"given":"Sarah R.","family":"MacEwan","sequence":"first","affiliation":[{"name":"1Division of General Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"2Center for the Advancement of Team Science, Analytics, and Systems Thinking, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChienWei","family":"Chiang","sequence":"additional","affiliation":[{"name":"3Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"4Secondary Data Core, Center for Clinical and Translational Science, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-9746","authenticated-orcid":false,"given":"Sarah H.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"5Center for Child Health Equity and Outcomes Research, Abigail Wexner Research Institute, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-8139","authenticated-orcid":false,"given":"Susan","family":"Creary","sequence":"additional","affiliation":[{"name":"5Center for Child Health Equity and Outcomes Research, Abigail Wexner Research Institute, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-3508","authenticated-orcid":false,"given":"Chyongchiou J.","family":"Lin","sequence":"additional","affiliation":[{"name":"6College of Nursing, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Madison","family":"Hyer","sequence":"additional","affiliation":[{"name":"4Secondary Data Core, Center for Clinical and Translational Science, The Ohio State University, Columbus, OH"},{"name":"7Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-6521","authenticated-orcid":false,"given":"Robert M.","family":"Cronin","sequence":"additional","affiliation":[{"name":"1Division of General Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"2Center for the Advancement of Team Science, Analytics, and Systems Thinking, College of Medicine, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"issue":"16","key":"2024010913192732000_bib1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024010913192732000_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.24235","article-title":"Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: the last 40 years","volume":"91","author":"Chaturvedi","year":"2016","journal-title":"Am J Hematol"},{"key":"2024010913192732000_bib3","unstructured":"Centers for Disease Control and Prevention\n          . Data & Statistics on Sickle Cell Disease. Accessed 20 October 2022. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html."},{"key":"2024010913192732000_bib4","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jval.2018.07.826","article-title":"The economic burden of sickle cell disease in the United States","volume":"21","author":"Huo","year":"2018","journal-title":"Value Health"},{"issue":"11","key":"2024010913192732000_bib5","first-page":"1345","article-title":"Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers","volume":"23","author":"Shah","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"2024010913192732000_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.36469\/9667","article-title":"Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study","volume":"6","author":"Shah","year":"2019","journal-title":"J\u00a0Health Econ Outcomes Res"},{"issue":"1","key":"2024010913192732000_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.36469\/jheor.2020.12852","article-title":"Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study","volume":"7","author":"Shah","year":"2020","journal-title":"J\u00a0Health Econ Outcomes Res"},{"year":"2015","author":"Jiang","key":"2024010913192732000_bib8"},{"year":"2006","author":"Jiang","key":"2024010913192732000_bib9"},{"year":"2005","author":"Stanton","key":"2024010913192732000_bib10"},{"issue":"3","key":"2024010913192732000_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/SLA.0000000000002663","article-title":"Hot spotting as a strategy to identify high-cost surgical populations","volume":"269","author":"Shubeck","year":"2019","journal-title":"Ann Surg"},{"issue":"4","key":"2024010913192732000_bib12","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.jemermed.2015.09.002","article-title":"Characteristics of hospital and emergency care super-utilizers with multiple chronic conditions","volume":"50","author":"Harris","year":"2016","journal-title":"J\u00a0Emerg Med"},{"issue":"8","key":"2024010913192732000_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/M18-0085","article-title":"Persistence and drivers of high-cost status among dual-eligible Medicare and Medicaid beneficiaries: an observational study","volume":"169","author":"Figueroa","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"2024010913192732000_bib14","doi-asserted-by":"crossref","first-page":"e023113","DOI":"10.1136\/bmjopen-2018-023113","article-title":"Systematic review of high-cost patients\u2019 characteristics and healthcare utilisation","volume":"8","author":"Wammes","year":"2018","journal-title":"BMJ Open"},{"issue":"11","key":"2024010913192732000_bib15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jamasurg.2019.2979","article-title":"Novel machine learning approach to identify preoperative risk factors associated with super-utilization of Medicare expenditure following surgery","volume":"154","author":"Hyer","year":"2019","journal-title":"JAMA Surg"},{"issue":"3","key":"2024010913192732000_bib16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/SLA.0000000000003426","article-title":"Characterizing and assessing the impact of surgery on healthcare spending among Medicare enrolled preoperative super-utilizers","volume":"270","author":"Hyer","year":"2019","journal-title":"Ann Surg"},{"issue":"45","key":"2024010913192732000_bib17","first-page":"40","article-title":"The hot spotters","volume":"86","author":"Gawande","year":"2011","journal-title":"New Yorker"},{"issue":"3","key":"2024010913192732000_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.23912","article-title":"Intensive management of high-utilizing adults with sickle cell disease lowers admissions","volume":"90","author":"Koch","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2024010913192732000_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5811\/westjem.2016.11.32273","article-title":"A\u00a0patient-centered emergency department management strategy for sickle-cell disease super-utilizers","volume":"18","author":"Simpson","year":"2017","journal-title":"West J Emerg Med"},{"issue":"2","key":"2024010913192732000_bib20","doi-asserted-by":"crossref","first-page":"e0247324","DOI":"10.1371\/journal.pone.0247324","article-title":"Characteristics of sickle cell patients with frequent emergency department visits and hospitalizations","volume":"16","author":"Kidwell","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"2024010913192732000_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.21515","article-title":"The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization","volume":"84","author":"Carroll","year":"2009","journal-title":"Am J Hematol"},{"issue":"5 suppl","key":"2024010913192732000_bib22","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.acap.2014.02.008","article-title":"Identifying sickle cell disease cases using administrative claims","volume":"14","author":"Reeves","year":"2014","journal-title":"Acad Pediatr"},{"issue":"6","key":"2024010913192732000_bib23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"7","key":"2024010913192732000_bib24","doi-asserted-by":"crossref","first-page":"e0214355","DOI":"10.1371\/journal.pone.0214355","article-title":"Sickle cell disease complications: prevalence and resource utilization","volume":"14","author":"Shah","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"2024010913192732000_bib25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/pbc.24459","article-title":"Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs","volume":"60","author":"Blinder","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024010913192732000_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","article-title":"Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2024010913192732000_bib27","first-page":"25","article-title":"How do Medicare physician fees compare with private payers?","volume":"14","author":"Miller","year":"1993","journal-title":"Health Care Financ Rev"},{"issue":"9","key":"2024010913192732000_bib28","first-page":"1121","article-title":"The economic burden of end-organ damage among Medicaid patients with sickle cell disease in the United States: a Population-Based Longitudinal Claims Study","volume":"26","author":"Campbell","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"2","key":"2024010913192732000_bib29","doi-asserted-by":"crossref","first-page":"e0229710","DOI":"10.1371\/journal.pone.0229710","article-title":"Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease","volume":"15","author":"Saraf","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"2024010913192732000_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s41669-022-00330-w","article-title":"Medical and non-medical costs of sickle cell disease and treatments from a US perspective: a systematic review and landscape analysis","volume":"6","author":"Baldwin","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"23","key":"2024010913192732000_bib31","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1182\/bloodadvances.2021004864","article-title":"Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial","volume":"5","author":"Hsu","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"2024010913192732000_bib32","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1182\/bloodadvances.2022008965","article-title":"The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2024010913192732000_bib33","first-page":"4775","article-title":"Debating the future of sickle cell disease curative therapy: haploidentical hematopoietic stem cell transplantation vs. gene therapy","volume":"11","author":"Kassim","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"suppl 1","key":"2024010913192732000_bib34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2022-157460","article-title":"Gene therapy equity in sickle cell disease: distributional cost-effectiveness analysis (DCEA) of gene therapy vs. standard-of-care in patients with sickle cell disease in the United States","volume":"140","author":"Goshua","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024010913192732000_bib35","doi-asserted-by":"crossref","first-page":"10838-13","DOI":"10.1038\/s41598-021-90405-1","article-title":"Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease","volume":"11","author":"Salcedo","year":"2021","journal-title":"Sci Rep"},{"key":"2024010913192732000_bib36","doi-asserted-by":"crossref","first-page":"100925","DOI":"10.1016\/j.blre.2021.100925","article-title":"l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope?","volume":"53","author":"Leibovitch","year":"2022","journal-title":"Blood Rev"},{"issue":"4","key":"2024010913192732000_bib37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NCQ.0000000000000644","article-title":"Health care hotspotting: a scoping review","volume":"37","author":"Alderman","year":"2022","journal-title":"J\u00a0Nurs Care Qual"},{"issue":"12","key":"2024010913192732000_bib38","doi-asserted-by":"crossref","first-page":"e28703","DOI":"10.1002\/pbc.28703","article-title":"Administrative data identify sickle cell disease: a critical review of approaches in US health services research","volume":"67","author":"Grosse","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2024010913192732000_bib39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/bloodadvances.2018017541","article-title":"Identification of patients with hemoglobin SS\/S\u03b20 thalassemia disease and pain crises within electronic health records","volume":"2","author":"Singh","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2024010913192732000_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7109a1","article-title":"Surveillance for sickle cell disease\u2014Sickle Cell Data Collection Program, two states, 2004\u20132018","volume":"71","author":"Snyder","year":"2022","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"2024010913192732000_bib41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/jha2.575","article-title":"Treatment patterns and burden of complications associated with sickle cell disease: a US retrospective claims analysis","volume":"3","author":"Manwani","year":"2022","journal-title":"EJHaem"},{"issue":"1","key":"2024010913192732000_bib42","first-page":"1140","article-title":"Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis","volume":"25","author":"Gallagher","year":"2022","journal-title":"J\u00a0Med Econ"},{"key":"2024010913192732000_bib43","unstructured":"American Society of Hematology\n          . ASH Research Registry. Accessed 28 September 2023. https:\/\/www.hematology.org\/research\/research-collaborative-data-hub."},{"year":"2021","author":"Szuber","key":"2024010913192732000_bib44"},{"issue":"11","key":"2024010913192732000_bib45","doi-asserted-by":"crossref","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2024010913192732000_bib46","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s40273-021-01072-z","article-title":"The use of cost-effectiveness analysis in sickle cell disease: a critical review of the literature","volume":"39","author":"Jiao","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2024010913192732000_bib47","doi-asserted-by":"crossref","first-page":"e0269703","DOI":"10.1371\/journal.pone.0269703","article-title":"Economic burden of sickle cell disease in Brazil","volume":"17","author":"Silva-Pinto","year":"2022","journal-title":"PLoS One"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/224\/2180465\/blooda_adv-2023-010813-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/224\/2180465\/blooda_adv-2023-010813-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T13:20:01Z","timestamp":1704806401000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/224\/498848\/Comparing-super-utilizers-and-lower-utilizers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010813","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}